Mortality associated with neurofibromatosis 1: A cohort study of 1895 patients in 1980-2006 in France

Orphanet Journal of Rare Diseases

Volumn 6, Issue 1, 2011, Pages

  Duong, Tu Anh ^a,b   Sbidian, Emilie ^a,b   Valeyrie Allanore, Laurence ^a,b   Vialette, Cédric ^a   Ferkal, Salah ^a,b   Hadj Rabia, Smal ^c   Glorion, Christophe ^c   Lyonnet, Stanislas ^c   Zerah, Michel ^c   Kemlin, Isabelle ^d   Rodriguez, Diana ^d,e   Bastuji Garin, Sylvie ^a,b   Wolkenstein, Pierre ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d ARMAND TROUSSEAU HOSPITAL   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CAUSE OF DEATH; CHILD; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROFIBROMATOSIS; RETROSPECTIVE STUDY; SCHOOL CHILD; STANDARDIZED MORTALITY RATIO; AGED; GENETICS; LIFE EXPECTANCY; MIDDLE AGED; NERVE SHEATH TUMOR; PRESCHOOL CHILD; RISK FACTOR; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FRANCE; GENES, NEUROFIBROMATOSIS 1; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; RISK FACTORS; YOUNG ADULT;

EID: 79955503281     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-6-18     Document Type: Article

References (19)

1. A genetic study of von Recklinghausen neurofibromatosis in south east Wales Prevalence, fitness, mutation rate, and effect of parental transmission on severity. SM Huson DA Compston P Clark PSI Harper, J Med Genet 1989 26 704 11 10.1136/jmg.26.11.704 2511318 (Pubitemid 19270599)
2. Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987. National Institutes of Health, Neurofibromatosis 1988 1 172 8 3152465
3. Molecular genetics of neurofibromatosis type 1 (NF1). MH Shen PS Harper M Upadhyaya, J Med Genet 1996 33 2 17 10.1136/jmg.33.1.2 8825042 (Pubitemid 26025089)
4. Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Goteborg, Sweden. M Zoller B Rembeck HO Akesson L Angervall, Acta Derm Venereol 1995 75 136 40 7604643
5. Long-term follow-up of von Reckilinghausen neurofibromatosis. Survival and malignant neoplams. SAMJ Sorensen A Nielsen, N England J Med 1986 17 1010 5 (Pubitemid 16113061)
6. Clinical risk factors for mortality in patients with neurofibromatosis 1: a cohort study of 378 patients. K Khosrotehrani S Bastuji-Garin J Zeller J Revuz P Wolkenstein, Arch Dermatol 2003 139 187 91 10.1001/archderm.139.2.187 12588224 (Pubitemid 36216256)
7. Subcutaneous neurofibromas are associated with mortality in neurofibromatosis 1: a cohort study of 703 patients. K Khosrotehrani S Bastuji-Garin VM Riccardi P Birch JM Friedman P Wolkenstein, Am J Med Genet A 2005 132A 49 53 10.1002/ajmg.a.30394 15523617 (Pubitemid 40070560)
8. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. LTD Walker D Easton B Ponder M Ponder I Frayling D Baralle, Br J Cancer 2006 17 233 8 (Pubitemid 44050923)
9. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. SA Rasmussen Q Yang JM Friedman, Am J Hum Genet 2001 68 1110 8 10.1086/320121 11283797 (Pubitemid 32424410)
10. Statistical methods in cancer research Volume II - The design and analysis of cohort studies. NE Breslow NE Day, IARC Sci Publ 1987 82 1 406 3329634
11. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. JM Friedman PH Birch, Am J Med Genet 1997 70 138 43 10.1002/(SICI)1096-8628(19970516)70:2<138::AID-AJMG7>3.0.CO;2-U 9128932 (Pubitemid 27184570)
12. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. DG Evans ME Baser J McGaughran S Sharif E Howard A Moran, J Med Genet 2002 39 311 4 10.1136/jmg.39.5.311 12011145 (Pubitemid 34526349)
13. Association between benign and malignant peripheral nerve sheath tumors in NF1. T Tucker P Wolkenstein J Revuz J Zeller JM Friedman, Neurology 2005 65 205 11 10.1212/01.wnl.0000168830.79997.13 16043787 (Pubitemid 41022362)
14. NF-1Score: a prediction score for internal neurofibromas in neurofibromatosis-1. EWP Sbidian L Valeyrie-Allanore D Rodriguez S Hadj-Rabia S Ferkal JP Lacour JC Leanoard L Taillandier S Sportich P Berbis S Bastuji-Garin, J Invest Dermatol 2010 130 2173 8 10.1038/jid.2010.100 20428190
15. Mortality of neurofibromatosis in Japan, 1968-1992. Y Imaizumi, J Dermatol 1995 22 191 5 7738275
16. Schwann cells from human neurofibromas show increased proliferation rates under the influence of progesterone. AWU Overdiek E Mayatepek T Rosenbaum, Pediatr Res 2008 64 :40 3 10.1203/PDR.0b013e31817445b8 18360307
17. An orthotopic xenograft model of intraneural NF1 MPNST suggests a potential association between steroid hormones and tumor cell proliferation. GQLH Perrin L Fishbein SA Thomson MS Hwang MT Scarborough AT Yachnis MR Wallace TH Mareci D Muir, Lab Invest 2007 87 1092 102 10.1038/labinvest.3700675 17876295 (Pubitemid 47609027)
18. Analysis of steroid hormone effects on xenografted human NF1 tumor schwann cells. HZX Li L Fishbein F Kweh M Campbell-Thompson GQ Perrin D Muir M Wallace, Cancer Biol Ther 2010 15 758 64
19. Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independant manner. SJEJ Byer NM Brossier BJ Clodfelder-Miller AN Turk AJ Carroll JC Kappes KR Zinn JK Prasain SL Carroll, Neuro Oncol 2011 13 28 41 10.1093/neuonc/noq146 21075781